What's Happening?
Immunome, Inc. will present data from its Phase 3 RINGSIDE trial at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial evaluates varegacestat, a gamma secretase inhibitor, in patients with progressing desmoid tumors. The presentation
will highlight the trial's efficacy and safety results, building on positive topline data reported in December 2025. The RINGSIDE trial is the largest randomized study in this patient population, focusing on progression-free survival and other key endpoints. Immunome plans to submit a New Drug Application for varegacestat to the FDA in Q2 2026.
Why It's Important?
The presentation of the RINGSIDE trial data at ASCO underscores the potential of varegacestat as a new treatment option for desmoid tumors, a rare and challenging condition. The trial's results could lead to a new standard of care, improving outcomes for patients with limited treatment options. The upcoming FDA submission represents a critical step towards bringing this therapy to market, potentially benefiting a broader patient population and advancing the field of targeted cancer therapies.
What's Next?
Following the ASCO presentation, Immunome will focus on submitting the New Drug Application to the FDA, aiming for regulatory approval. The company will also continue the open-label extension phase of the RINGSIDE trial to gather additional data on varegacestat's long-term efficacy and safety. Successful approval could lead to the commercialization of varegacestat, providing a new therapeutic option for patients with desmoid tumors.
